Martina Recalde

Martina Recalde

Auto-generated profile, based on publicly available information

Martina Recalde

Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol) Barcelona Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2022 in International Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
MRMartina Recalde
Martina Recalde
CRClara Rodríguez
Clara Rodríguez
EBEdward Burn
Edward Burn
MFMarc Far
Marc Far
DGDarío García
Darío García
TDTalita Duarte-Salles
Talita Duarte-Salles
Key FeaturesThe Information System for Research in Primary Care (SIDIAP) is a database of population-wide primary care electronic health records that was create

3 November 2021 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
ERElena Roel
Elena Roel
APAndrea Pistillo
Andrea Pistillo
MRMartina Recalde
Martina Recalde
SFSergio Fernández‐Bertolín
Sergio Fernández‐Bertolín
MAMaría Aragón
María Aragón
TDTalita Duarte‐Salles
Talita Duarte‐Salles
The relationship between cancer and coronavirus disease 2019 (COVID‐19) infection and severity remains poorly understood. We conducted a population‐based cohort study between 1 March and 6 May 2020 describing the associations between cancer and risk of COVID‐19 diagnosis, hospitalisation and COVID‐19‐related death. Data were obtained from the Information System for Research in Primary Care (SIDIAP) database, including primary care electronic health records from ~80% of the population in Catalonia, Spain. Cancer was defined as any primary invasive malignancy excluding non‐melanoma skin cancer. We estimated adjusted hazard ratios (aHRs) for the risk of COVID‐19 (outpatient) clinical diagnosis, hospitalisation (with or without a prior COVID‐19 diagnosis) and COVID‐19‐related death using Cox proportional hazard regressions. Models were estimated for the overall cancer population and by years since cancer diagnosis (<1 year, 1‐5 years and ≥5 years), sex, age and cancer type; and adjusted for age, sex, smoking status, deprivation and comorbidities. We included 4 618 377 adults, of which 260 667 (5.6%) had a history of cancer. A total of 98 951 individuals (5.5% with cancer) were diagnosed, and 6355 (16.4% with cancer) were directly hospitalised with COVID‐19. Of those diagnosed, 6851 were subsequently hospitalised (10.7% with cancer), and 3227 died without being hospitalised (18.5% with cancer). Among those hospitalised, 1963 (22.5% with cancer) died. Cancer was associated with an increased risk of COVID‐19 diagnosis (aHR: 1.08; 95% confidence interval [1.05‐1.11]), direct COVID‐19 hospitalisation (1.33 [1.24‐1.43]) and death following hospitalisation (1.12 [1.01‐1.25]). These associations were stronger for patients recently diagnosed with cancer, aged <70 years, and with haematological cancers. These patients should be prioritised in COVID‐19 vaccination campaigns and continued non‐pharmaceutical interventions.

23 July 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
MRMartina Recalde
Martina Recalde
APAndrea Pistillo
Andrea Pistillo
SFSergio Fernandez-Bertolin
Sergio Fernandez-Bertolin
ERElena Roel
Elena Roel
MAMaria Aragon
Maria Aragon
TDTalita Duarte-Salles
Talita Duarte-Salles
Context A comprehensive understanding of the association between body mass index (BMI) and coronavirus disease 2019 (COVID-19) is still lacking. Objective To investigate associations between BMI and risk of COVID-19 diagnosis, hospitalization with COVID-19, and death after a COVID-19 diagnosis or hospitalization (subsequent death), accounting for potential effect modification by age and sex. Design Population-based cohort study. Setting Primary care records covering >80% of the Catalan population, linked to regionwide testing, hospital, and mortality records from March to May 2020. Participants Adults (≥18 years) with at least 1 measurement of weight and height. Main outcome measures Hazard ratios (HR) for each outcome. Results We included 2 524 926 participants. After 67 days of follow-up, 57 443 individuals were diagnosed with COVID-19, 10 862 were hospitalized with COVID-19, and 2467 had a subsequent death. BMI was positively associated with being diagnosed and hospitalized with COVID-19. Compared to a BMI of 22 kg/m2, the HR (95% CI) of a BMI of 31 kg/m2 was 1.22 (1.19-1.24) for diagnosis and 1.88 (1.75-2.03) and 2.01 (1.86-2.18) for hospitalization without and with a prior outpatient diagnosis, respectively. The association between BMI and subsequent death was J-shaped, with a modestly higher risk of death among individuals with BMIs ≤ 19 kg/m2 and a more pronounced increasing risk for BMIs ≥ 40 kg/m2. The increase in risk for COVID-19 outcomes was particularly pronounced among younger patients. Conclusions There is a monotonic association between BMI and COVID-19 diagnosis and hospitalization risks but a J-shaped relationship with mortality. More research is needed to unravel the mechanisms underlying these relationships.

8 July 2022 in Environmental Research
Verified
Journal Article
Closed access
ITIsaura Terre-Torras
Isaura Terre-Torras
MRMartina Recalde
Martina Recalde
YDYesika Díaz
Yesika Díaz
JBJeroen de Bont
Jeroen de Bont
MBMatthew Bennett
Matthew Bennett
TDTalita Duarte-Salles
Talita Duarte-Salles

16 July 2021 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
ERElena Roel
Elena Roel
APAndrea Pistillo
Andrea Pistillo
MRMartina Recalde
Martina Recalde
ASAnthony G. Sena
Anthony G. Sena
SFSergio Fernández-Bertolín
Sergio Fernández-Bertolín
TDTalita Duarte-Salles
Talita Duarte-Salles
Background: We described the demographics, cancer subtypes, comorbidities, and outcomes of patients with a history of cancer and coronavirus disease 2019 (COVID-19). Second, we compared patients hospitalized with COVID-19 to patients diagnosed with COVID-19 and patients hospitalized with influenza. Methods: We conducted a cohort study using eight routinely collected health care databases from Spain and the United States, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of cancer were included: (i) diagnosed with COVID-19, (ii) hospitalized with COVID-19, and (iii) hospitalized with influenza in 2017 to 2018. Patients were followed from index date to 30 days or death. We reported demographics, cancer subtypes, comorbidities, and 30-day outcomes. Results: We included 366,050 and 119,597 patients diagnosed and hospitalized with COVID-19, respectively. Prostate and breast cancers were the most frequent cancers (range: 5%–18% and 1%–14% in the diagnosed cohort, respectively). Hematologic malignancies were also frequent, with non-Hodgkin's lymphoma being among the five most common cancer subtypes in the diagnosed cohort. Overall, patients were aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 2% to 14% and from 6% to 26% in the diagnosed and hospitalized COVID-19 cohorts, respectively. Patients hospitalized with influenza (n = 67,743) had a similar distribution of cancer subtypes, sex, age, and comorbidities but lower occurrence of adverse events. Conclusions: Patients with a history of cancer and COVID-19 had multiple comorbidities and a high occurrence of COVID-19-related events. Hematologic malignancies were frequent. Impact: This study provides epidemiologic characteristics that can inform clinical care and etiologic studies.

28 September 2023 in Cancer Medicine
Verified
Journal Article
Open access
MRMartina Recalde
Martina Recalde
APAndrea Pistillo
Andrea Pistillo
VVVivian Viallon
Vivian Viallon
EFEmma Fontvieille
Emma Fontvieille
TDTalita Duarte‐Salles
Talita Duarte‐Salles
HFHeinz Freisling
Heinz Freisling
Background: We investigated the association between body mass index (BMI) and obesity‐related cancer risk among individuals with/without incident hypertension (HTN), type 2 diabetes mellitus (T2DM), and cardiovascular disease (CVD) and the joint associations of overweight/obesity (BMI ≥25 kg/m2) and each cardiometabolic condition with obesity‐related cancer riskMethods: We conducted a population‐based cohort (n = 1,774,904 individuals aged ≥40 years and free of cancer and cardiometabolic conditions at baseline) study between 2010 and 2018 with electronic health records from Spain. Our main outcome measures were hazard ratios (HRs) for incident obesity‐related cancers and relative excess risk due to interaction (RERI).Results: A total of 38,082 individuals developed obesity‐related cancers after a median of 8 years of follow‐up. The positive association between BMI and obesity‐related cancer risk was similar among individuals free of cardiometabolic conditions (hazard ratio, HR per 5 kg/m2: 1.08, 95% confidence interval, CI: 1.06–1.10) and with incident HTN (1.05, 1.01–1.08). The association among those with incident T2DM was null (0.98, 0.93–1.03). There was a positive additive interaction between overweight/obesity and CVD (relative excess risk due to interaction [RERI]: 0.19 [0.09, 0.30]), meaning that the combined association was 0.19 more than the sum of the individual associations. In contrast, a RERI of −0.24 (−0.28, −0.20) was observed for the combined association between overweight/obesity and T2DM.Conclusions: Public health strategies to reduce overweight can help prevent cancer cases among the general population and individuals with incident HTN/CVD. Further, weight‐loss interventions seem to lead to a greater cancer risk reduction among individuals with CVD.